Related Experiment Video
Updated: Mar 20, 2026
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
RASopathy Gene Mutations in Melanoma
Ruth Halaban1, Michael Krauthammer2
1Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA.
Abstract:
Next-generation sequencing of melanomas has unraveled critical driver genes and genomic abnormalities, mostly defined as occurring at high frequency. In addition, less abundant mutations are present that link melanoma to a set of disorders, commonly called RASopathies. These disorders, which include neurofibromatosis and Noonan and Legius syndromes, harbor germline mutations in various RAS/mitogen-activated protein kinase signaling pathway genes. We highlight shared amino acid substitutions between this set of RASopathy mutations and those observed in large-scale melanoma sequencing data, uncovering a significant overlap. We review the evidence that these mutations activate the RAS/mitogen-activated protein kinase pathway in melanoma and are involved in melanomagenesis. Furthermore, we discuss the observations that two or more RASopathy mutations often co-occur in melanoma and may act synergistically on activating the pathway.
Insights
Melanoma harbors mutations found in RASopathies, a group of genetic disorders. These mutations activate the RAS/mitogen-activated protein kinase pathway, contributing to melanoma development and potentially acting synergistically.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Next-generation sequencing (NGS) has identified high-frequency driver genes in melanoma.
- Less common mutations in melanoma are linked to genetic disorders known as RASopathies.
Purpose of the Study:
- To investigate the overlap between RASopathy-associated mutations and melanoma.
- To explore the role of these shared mutations in melanoma development and pathway activation.
Main Methods:
- Comparative analysis of large-scale melanoma sequencing data.
- Review of existing literature on RASopathies and melanoma genetics.
- Examination of amino acid substitutions in RAS/mitogen-activated protein kinase (MAPK) pathway genes.
Main Results:
- Significant overlap identified between RASopathy mutations and those found in melanoma.
- Evidence suggests these mutations activate the RAS/MAPK pathway in melanoma.
- Co-occurrence of multiple RASopathy mutations in melanoma was observed, potentially enhancing pathway activation.
Conclusions:
- Mutations typically associated with RASopathies play a role in melanoma pathogenesis.
- The RAS/MAPK pathway is a key target in understanding melanoma driven by these mutations.
- Synergistic effects of co-occurring RASopathy mutations may accelerate melanoma progression.
Related Concept Videos
02:38The Ras Gene
Ras is a...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:20The Retinoblastoma Gene
02:38The Ras Gene
01:24Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
01:35Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...